Domestic medical innovation continues to accelerate, the process of technology landing and clinical translation accelerates, and high-quality medical assets are the core targets of capital and industry key layout.

This issue selects six high-value medical innovation assets, covering six popular tracks including tumor vaccines, innovative drugs, regenerative medicine, rehabilitation medicine, anti-inflammatory biomaterials, and smart healthcare.All projects are in a critical window period of clinical advancement, product iteration, and commercial expansion, adapting to diverse cooperation models such as equity investment, industry mergers and acquisitions, technology BD, and pipeline cooperation. We sincerely invite investment institutions, listed pharmaceutical companies, industry platforms, and overseas teams to collaborate and explore incremental opportunities in the medical innovation industry.

 The following is an introduction to medical assets for this period:

---

1、 Broad spectrum KRAS therapeutic tumor vaccine platform

This project focuses on the high incidence, high mortality, and high barrier track of KRAS mutation driven solid tumors. The core asset is a prefabricated broad-spectrum KRAS therapeutic tumor vaccine, which has successfully obtained NMPA Phase I/II IND approval and officially entered the clinical development stage. The product accurately covers more than 90% of clinical KRAS hot spot mutations, fully adapts to lung cancer, colorectal cancer, pancreatic cancer and other high incidence solid tumor indications, and can cover 20% – 25% of the global cancer mutation population, with wide target coverage and strong clinical applicability.

The project adopts mature peptide vaccine technology path, which has multiple advantages such as clear antigen epitopes, stable process, mature quality control, convenient administration, and controllable cost. Compared to traditional KRAS small molecule inhibitors that can only cover a single mutant subtype, this product achieves broad-spectrum coverage of multiple mutations; Compared to personalized vaccines and mRNA vaccines, the project has stronger feasibility and certainty in terms of mass production, quality control, cold chain transportation, and commercial implementation. Early clinical data overseas has clearly verified that this technology route can significantly prolong the median survival time of patients and demonstrate excellent long-term survival benefit potential.

At the track level, KRAS has a large number of patients with solid tumors. The total number of domestic core indications can cover more than 4 million patients, and the overall market space exceeds 190 billion yuan. Among them, the market size of lung cancer, colorectal cancer, and pancreatic cancer has exceeded 30 billion yuan, with sufficient commercial potential. Relying on domestic first-class innovative drug qualifications, products can enjoy up to 6 years of drug data protection after being launched, building a dual monopoly barrier of patents and data, effectively ensuring long-term market returns. The current valuation of the project is 200 million yuan, and this round of financing plans to raise 50 million yuan. The funds will be mainly used to promote phase I/II clinical trials of the core product, conduct IIT combination therapy research, establish a domestic production system, and subsequent registration and application work, accelerating the clinical validation and commercialization of the product.

2、 HA35 Low Molecular Weight Hyaluronic Acid Technology Platform

This project relies on the independent HA35 low molecular weight hyaluronic acid core active technology platform, focusing on the intervention and refined health management of inflammation, pain, and itching diseases, and building a differentiated bioactive product system. Different from conventional hyaluronic acid materials, the exclusive HA35 small molecule material has unique biological activity and can accurately target the regulation of TRPV1/TRPA1 inflammatory pain ion channels. It effectively inhibits the body’s inflammatory response, blocks itching and pain signal transmission under high concentration conditions, and achieves efficient anti-inflammatory, anti itch, and analgesic effects. The technical mechanism is clear and the target of action is clear, breaking through the traditional hyaluronic acid’s single property of only moisturizing and repairing.

Based on the advantages of core technology, the project has completed the matrix layout of multi dosage products, landing gel for external use, oral care gel, oral preparations, injections and other products, comprehensively covering multiple scenarios such as skin inflammation care, oral surgery repair, local pain relief, chronic inflammation intervention and so on, opening up the two major application racetracks of consumer health and clinical medicine. Compared to traditional chemical anti-inflammatory and analgesic products, this bioactive technology route has higher safety, is suitable for long-term home care and postoperative rehabilitation scenarios, has no obvious side effects, and has strong product differentiation advantages.

Anti inflammation and pain relief, as well as skin and oral health, are essential tracks in the field of big health, covering multiple high growth niche markets such as skin care, oral medicine, sports injuries, and chronic pain management. With the upgrading of national health consumption and the expansion of home health care demand, the industry market size continues to steadily climb. The project adopts a dual track commercial layout of consumer health and medical products, quickly entering the mass market with low threshold consumer level products, accumulating brand reputation and channel resources, and achieving a positive cash flow cycle; At the same time, we will deeply cultivate the high value-added medical track, continuously expand the application scenarios of clinical adjuvant therapy, and build a product matrix with full price bands and full scenarios. Relying on the exclusive HA35 technology barrier, the project can achieve sustained commercial growth through multi product driving, gradually building a benchmark technology platform in the field of anti-inflammatory and analgesic, and laying a core foundation for subsequent iteration of medical grade products, pipeline expansion, industrialization, and international cooperation.

3、 Stroke sequelae biophotonic rehabilitation platform

This project focuses on the golden track of post-stroke sequelae rehabilitation, with a core asset of a non-invasive biophotonic rehabilitation treatment system. It focuses on neurological function repair, blood circulation improvement, and cell repair intervention for stroke patients, and is suitable for hospital rehabilitation departments, neurological specialty hospitals, professional rehabilitation centers, and home continuous rehabilitation scenarios.

The project adopts an innovative and stable photon environment intervention technology path, which can comprehensively act on core links such as nerve injury repair, neuromuscular signal transduction, blood circulation, energy metabolism regulation, and inflammation and pain control, accurately solving the multiple rehabilitation problems of post-stroke sequelae. At present, the product has completed initial clinical research, and the technical efficacy has been preliminarily verified. At the same time, relying on a sound international patent layout, a core intellectual property barrier has been constructed. With the core advantages of non invasiveness, safety, and strong adaptability, the seamless connection between professional treatment in the hospital and home-based continuous rehabilitation has been achieved. Compared with traditional rehabilitation methods, the adaptation scenarios are wider and the rehabilitation sustainability is stronger. It is an innovative auxiliary treatment solution in the field of stroke rehabilitation.

Stroke rehabilitation is a highly demanded, long-term, and high barrier track with significant market growth. There are approximately 93.8 million surviving stroke patients worldwide, with an annual increase of 11.9 million cases; There are currently over 13 million patients in China, and it is expected to exceed 30 million by 2030. The number of patients with sequelae such as hemiplegia, speech and swallowing disorders, nerve damage, and sleep disorders is huge, and the demand for long-term rehabilitation outside the hospital is extremely rigid. According to calculations, the domestic rehabilitation market size is about 130 billion yuan, and the international market size is 14 billion US dollars, with broad commercial space. The project aims to establish a diversified business model, covering multiple channels such as cooperation with public hospitals, settlement of rehabilitation centers, and sales and leasing of home equipment. We plan to raise $50 million in this round of financing, with a focus on technology iteration research and development, production line implementation, market expansion, and team operation. We will give priority to deepening the domestic market, building a standardized rehabilitation treatment center and hospital cooperation network, and quickly seize the dividends of innovative stroke rehabilitation medical equipment at home and abroad.

4、 Autologous stem cell small molecule reversal technology platform

This project deeply cultivates the innovation and transformation track of autologous stem cells, and builds a complete technology platform integrating the preparation, storage, and clinical application transformation of blood derived stem cells. The core technology of the project breaks through traditional bottlenecks in the industry, using peripheral blood mononuclear cells as raw materials and relying on a dedicated small molecule culture system to achieve cell reversal and targeted preparation. The entire process does not require viral vectors or gene editing, and the technical safety is extremely high. The process system is mature and efficient, and only 80-150ml of venous blood needs to be extracted to prepare primary autologous stem cells of over 100 million levels. Hematopoietic stem cells can be prepared in 6 days, and other types of stem cells can be prepared in 10 days, covering more than ten types of stem cells such as hematopoietic, neural, liver and kidney, and reproductive. Compared with allogeneic stem cell and bone marrow/adipose autologous stem cell technologies, this approach has core advantages such as non-invasive sampling, no need for matching, no immune rejection, and no risk of cross infection. It also does not require multiple generations of in vitro expansion, ensuring better cell activity and safety, and building a rare integrated stem cell preparation technology path in the industry.

The project has a profound technical accumulation and a perfect landing layout. The technology can be traced back to 1998, and after years of research and development, a complete intellectual property system has been formed. In 2024, a stem cell innovation team was formed in conjunction with the Shenzhen Advanced Institute of the Chinese Academy of Sciences. The core technical indicators have completed CNAS authoritative testing, and the technical compliance and professionalism have been fully verified.

At the commercial level, the project adopts the dual track model of domestic clinical research and development+overseas industrial implementation. Domestic IIT/IND cooperation is carried out relying on top three hospitals, focusing on diabetes, knee arthritis, chronic nephritis and other just in need indications; Overseas landing in the Hong Kong Hetao Industrial Park, layout production bases and medical care centers, and simultaneously build a strategic bank of adult autologous stem cells. The project forms a diversified income system including technical cooperation, cell preparation, cell storage, and health services. This round of Pre-A/A financing has begun, with a financing scale of 50-200 million yuan. The funds will be used for clinical research and development in tertiary hospitals, construction of Hong Kong industrialization bases, construction of stem cell banks, and market operation expansion, accelerating the clinical translation and commercialization of technology.

5、 Internet medicine and precision health management platform driven by doctor group

This project creates a one-stop smart medical service platform integrating doctor groups, Internet hospitals, precision diagnosis and treatment, and offline specialist clinics, and constructs a complete business closed-loop of “doctor resource integration online diagnosis and treatment cloud medicine service offline outpatient service precision detection full cycle health management”. The platform has completed the core layout of compliance, launched the comprehensive upgrade of smart medicine in 2023, and officially obtained the qualification of Internet hospital in 2024, with legal and compliant online diagnosis and treatment, follow-up, and health service capabilities. At present, the platform gathers over 1000 contracted physicians, including more than 500 director level experts, and can comprehensively undertake diversified medical services such as remote consultation, expert consultation, chronic disease follow-up, and patient lifecycle management. The project establishes a multi city collaborative operation system, with Beijing, Hangzhou, Shanghai, and Seoul responsible for doctor operations, technology research and development, domestic high-end medical integration, and international clinical cooperation, forming an efficient and standardized medical service and operation system.

The project focuses on the high value-added medical track, deepens the three core areas of endocrine chronic disease, tumor precise diagnosis and treatment, and high-end medical detection, implements the full process management system of type II diabetes, integrates cutting-edge projects such as gastroscopy detection, cell subpopulation detection, tumor vaccine, intestinal flora analysis, and links with Shanghai New Hongqiao International Medical Center, South Korea Lihua Women’s University Seoul Hospital and other top institutions at home and abroad to build a resource barrier for cross-border medical cooperation. Relying on mature online and offline service scenarios and the ability to import international resources, the project has formed a differentiated advantage in precision medical services.

At the capital level, the controlling entity of the project has landed in the US OTC market through RTO in 2021 and upgraded to the OTCQB sector in 2022. It has a mature overseas capital operation platform, which can effectively support subsequent business integration, scale expansion, and capitalization upgrading. It is one of the few rare smart medical projects that combines compliant medical qualifications, top doctor resources, international medical cooperation, and overseas capital base.

6、 Tumor Immunosurgery and Intratumoral Chemotherapy Immunotherapy Platform

This project focuses on two core essential scenarios for the treatment of solid tumors. It aims to prevent postoperative recurrence and metastasis in early-stage operable patients and address the pain points of low toxicity and high efficiency local treatment in mid to late stage patients. It has established an exclusive technical system with local slow-release delivery, intratumoral chemotherapy immunotherapy, and perioperative immune intervention as the core, achieving an integrated treatment effect of local tumor reduction, long-term drug release, and systemic immune activation.

The project has a systematic clinical accumulation of nearly 20 years. From 2004 to 2014, it entered into large-scale clinical application. From 2015 to 2023, it will form a standardized and mature treatment system. Relevant technical schemes have been continuously included in the national Guidelines for Interventional Treatment of pancreatic cancer, and the clinical authority and compliance are fully verified. At present, the project is constructing a multi-level asset structure of “mature clinical therapies+new drugs under development+extended pipelines”, accumulating over 100000 real-world clinical data cases. The core new drug has obtained the orphan drug qualification from the US FDA, completed Pre IND communication, and officially entered the stage of bilateral clinical development between China and the United States. The core mechanism can effectively inhibit circulating tumor cells, with an inhibition rate of up to 80%. With the support of comprehensive academic research, international papers, and overseas consulting teams, we can build strong technical and academic barriers.

The first project focuses on the pancreatic cancer track with high barrier and high mortality rate, and can be widely expanded to high incidence solid tumors such as liver cancer, stomach cancer, colorectal cancer, with broad commercial space. The annual market size of advanced pancreatic cancer in China exceeded 1.13 billion yuan, and the global core market reached 1.14 billion dollars; The domestic market space for perioperative treatment of operable solid tumors has exceeded 10.86 billion yuan. The project relies on a mature in-hospital treatment system, a well-established hospital cooperation network, and massive real case data to form a complete commercial closed loop of clinical implementation, product iteration, and scenario expansion. Mature therapies and innovative new drug pipelines are interconnected to sustainably tap into the incremental growth of the solid tumor treatment market. This round of financing plans to raise $50 million, which will be specifically used for the pharmaceutical development of core new drugs, non clinical research, promotion of clinical trials in China and the United States, and registration and application work, accelerating the completion of clinical validation and domestic and international market layout of core products, and quickly seizing the dividends of local immunotherapy for solid tumors.

---

The six major medical innovation assets of this period cover tumor new drugs, tumor vaccines, regenerative medicine, biological materials, rehabilitation equipment, and the smart healthcare track. They have high technical barriers, clear clinical progress, and mature commercialization, and are suitable for various industrial cooperation such as investment and financing, mergers and acquisitions, and BD.

Collaboration docking channel!!!!

If you are an investment institution, pharmaceutical/device listed company, overseas BD team, or industry partner interested in the above projects, please scan the QR code below to add WeChat and seize innovation opportunities in the medical and health field together!

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.